Its technology platform, seeQer, aims to remove the barriers associated with prior authorizations and financial transparency for diagnostic testing.

Susan Shepard

September 29, 2022

2 Min Read
Image courtesy of Oleksandr Perepelytsia / Alamy Stock Photo

Healthcare technology company, careviso, has raised more than $17 million in Series B funding to broadly expand its existing technology platform into the diagnostic space. The funding, led by Ballast Point Ventures, with participation from existing investors, Mercury, and Lytical Ventures, will enable the company to provide technology that aims to help patients clarify their cost of care while reducing administrative burdens for physicians.

The company’s technology platform, seeQuer, delivers real-time cost estimates, administrative requirements, approvals, and supports providers, payors, labs, and patients alike. seeQer is directly aligned with the No Surprises Act, which protects individuals covered under a variety of health plans from receiving surprise medical bills months after a service or procedure. The product, according to the company, solves the requirements surrounding the Good Faith Estimate and the Advanced Explanation of Benefits for diagnostic services at the point of care or ahead of time. The company plans to use the funding to support the growth of the platform so that it can be used to satisfy the No Surprises Act throughout the entire diagnostic space.

“Despite the evolution of our healthcare system, one of the largest challenges continues to exist around prior authorizations and transparency around costs, plaguing both physicians and patients alike,” said Andrew Mignatti, co-founder and CEO of careviso, in a company statement. “Through this latest fundraise, careviso will grow beyond its core focus on physicians as we pivot towards a broader part of the diagnostic testing process to solve the growing challenges for patients – reducing complexity and providing a clear picture of costs. With the support of our dedicated investors, we are excited for our next phase of development as we execute on our mission to remove the barriers associated with this critical area of the healthcare industry.”

More than 50% of OBGYN clinics in the United States are currently working with careviso. While OBGYN and oncology remain careviso’s core therapeutic areas, the company is prioritizing expansion into other therapeutic areas focusing on patient access, including radiology and endoscopy.

About the Author(s)

Susan Shepard

Susan Shepard is a freelance contributor to MD + DI.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like